MT1 expression has been studied in all breast cancer types and its association has been examined against multiple tumor characteristics: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, and the tumor grade, to name a few. This evidence concerns the gene ERBB2 and breast carcinoma.